Patents Assigned to NFlection Therapeutics, Inc.
  • Patent number: 11572344
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula where R1, R2, R2a, R3, R3a, and X are as described herein.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: February 7, 2023
    Assignee: NFLECTION THERAPEUTICS, INC.
    Inventors: John Kincaid, Matthew Duncton
  • Patent number: 11542271
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I): where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: January 3, 2023
    Assignee: NFLECTION THERAPEUTICS, INC.
    Inventors: John Kincaid, Matthew Duncton
  • Patent number: 11161845
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 2, 2021
    Assignee: Nflection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton
  • Patent number: 10988483
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 27, 2021
    Assignee: NFlection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton